$327 Million is the total value of Integral Health Asset Management, LLC's 72 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 51.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LHCG | Sell | LHC GROUP INC | $15,942,000 | -26.8% | 75,000 | -40.0% | 4.88% | -25.3% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $11,219,000 | +1.8% | 150,000 | -14.3% | 3.43% | +4.0% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $9,734,000 | +13.4% | 105,000 | -4.5% | 2.98% | +15.9% |
| NVRO | Sell | NEVRO CORP | $9,472,000 | +5.7% | 68,000 | -9.3% | 2.90% | +8.0% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $7,473,000 | -22.1% | 33,000 | -40.0% | 2.29% | -20.4% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $6,328,000 | -31.2% | 65,000 | -13.3% | 1.94% | -29.8% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $4,982,000 | -12.7% | 30,000 | -40.0% | 1.52% | -10.9% |
| CYTK | Sell | CYTOKINETICS INC | $4,330,000 | -46.0% | 200,000 | -41.2% | 1.32% | -44.8% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $4,200,000 | -47.6% | 120,000 | -20.0% | 1.28% | -46.5% |
| BAX | Sell | BAXTER INTL INC | $3,217,000 | -25.3% | 40,000 | -20.0% | 0.98% | -23.7% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $3,211,000 | -46.8% | 30,000 | -53.8% | 0.98% | -45.7% |
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $3,015,000 | -74.4% | 50,000 | -75.0% | 0.92% | -73.8% |
| CTLT | Sell | CATALENT INC | $2,998,000 | -59.1% | 35,000 | -65.0% | 0.92% | -58.2% |
| MOH | Sell | MOLINA HEALTHCARE INC | $2,746,000 | -61.4% | 15,000 | -62.5% | 0.84% | -60.6% |
| GOSS | Sell | GOSSAMER BIO INC | $2,482,000 | -29.3% | 200,000 | -25.9% | 0.76% | -27.8% |
| DXCM | Sell | DEXCOM INC | $2,473,000 | -59.3% | 6,000 | -60.0% | 0.76% | -58.5% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $2,330,000 | -47.6% | 30,000 | -62.5% | 0.71% | -46.4% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $1,439,000 | -48.5% | 80,000 | -27.3% | 0.44% | -47.4% |
| CHNG | Sell | CHANGE HEALTHCARE INC | $726,000 | -74.1% | 50,000 | -80.0% | 0.22% | -73.5% |
| BMYRT | Exit | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $0 | – | -150,000 | -100.0% | -0.16% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -10,000 | -100.0% | -0.31% | – |
| WBA | Exit | WALGREENS BOOTS ALLIANCE INC | $0 | – | -40,000 | -100.0% | -0.51% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -350,000 | -100.0% | -0.72% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -90,000 | -100.0% | -0.73% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -20,000 | -100.0% | -0.73% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -25,000 | -100.0% | -0.74% | – |
| Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -100,000 | -100.0% | -0.77% | – | |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -1.02% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -150,000 | -100.0% | -1.07% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -55,000 | -100.0% | -1.43% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -1.50% | – |
| LLY | Exit | LILLY ELI & CO | $0 | – | -35,000 | -100.0% | -1.72% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -25,000 | -100.0% | -1.77% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -125,000 | -100.0% | -1.98% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -125,000 | -100.0% | -2.08% | – |
| REGN | Exit | REGENERON PHARMACEUTICALS | $0 | – | -12,000 | -100.0% | -2.24% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -45,000 | -100.0% | -2.29% | – |
| DHR | Exit | DANAHER CORPORATION | $0 | – | -45,000 | -100.0% | -2.38% | – |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -120,000 | -100.0% | -4.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 15 | Q3 2023 | 4.7% |
| SAGE THERAPEUTICS INC | 15 | Q2 2023 | 5.0% |
| BIOMARIN PHARMACEUTICAL INC | 15 | Q2 2023 | 4.1% |
| ENVISTA HOLDINGS CORPORATION | 14 | Q3 2023 | 4.0% |
| AKERO THERAPEUTICS INC | 14 | Q3 2023 | 1.5% |
| REVVITY INC | 13 | Q3 2023 | 4.2% |
| BLUEPRINT MEDICINES CORP | 13 | Q3 2023 | 3.3% |
| PTC THERAPEUTICS INC | 13 | Q2 2023 | 1.7% |
| ELEVANCE HEALTH INC | 12 | Q3 2023 | 6.7% |
| NEVRO CORP | 12 | Q4 2022 | 4.5% |
View Integral Health Asset Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-12 |
| 13F-HR | 2022-02-02 |
View Integral Health Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.